Loading…
Longeveron Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -99.2% over 5Y.
today you would have $7.96▼ -99.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.06 | $17.30 | $136.00 | $322.00 | |
| P/S | 294.7x | 96.8x | 107.7x | 481.6x | 553.8x |
| P/B | 26.7x | 20.4x | 11.8x | 50.7x | 33.0x |
| EPS | -$1.29 | -$2.62 | -$10.22 | -$9.00 | |
| Profit margin | -1717.45% | -1893.58% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BNGOBionano Genomics, Inc. | $1.82 | — | 0.7x | — | -83.56% | $21.43M |
| COCPCocrystal Pharma, Inc. | $1.10 | — | 14.5x | — | -311.68% | $21.19M |
| LFWDLifeward Ltd. | $7.46 | — | 3.3x | — | -225.65% | $21.13M |
| CTSOCytosorbents Corp | $0.34 |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Company description provided by Yahoo Finance.
| -667.77% |
| -3020.17% |
| -1541.33% |
| ROE | -204.76% | -400.07% | -72.98% | -317.65% | -91.86% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -336.21% |
| $21.09M |
| RVPRetractable Technologies Inc | $0.73 | — | 0.3x | — | -4.51% | $21.85M |
| AKTXAkari Therapeutics Plc | $10.70 | — | 1.0x | — | -140.09% | $20.83M |